| Open Document File Size: 2,60 MBShare Result on Facebook
City Rockville / / Company Crane / Grainger / qD CO / Pharmaceuticals Inc. / / Country United States / New Zealand / / Event FDA Phase / / Facility U.S. National Library of Medicine / / IndustryTerm olodaterol inhalation solution / prevention of bronchospasm with reversible obstructive airway disease / inhalation solution / biologic product / manufacturing / ingredient products / combination products / aqueous solution / / MedicalCondition scar / ventricular premature beats / specific diseases / spontaneous and induced asthma / bronchospasm / COPD / tumors / uterine leiomyomas / disease / single cell necrosis / emphysema / reversible obstructive airway disease / chronic obstructive pulmonary disease / serious asthma / malignant leiomyosarcomas / Allergy / pulmonary / ovarian cysts / J Allergy / specific disease / ovarian leiomyomas / pulmonary absorption / severe asthma / chronic bronchitis / fibrosis / asthma / / Organization PULMONARY-ALLERGY DRUGS ADVISORY COMMITTEE / Food and Drug Administration / DRUGS ADVISORY COMMITTEE / Pediatric Advisory Committee / Division of Pulmonary / Review Division / FDA Advisory Committee / Advisory Committee / / Person Theresa M. Michele / Olo / / Position Prime Minister / Clinical Team Leader / / Product fluticasone propionate / Ventolin HFA / Combivent / ipratropium bromide / ProAir HFA / epinephrine / Proventil / albuterol / Symbicort / beta-2 / mometasone furoate / Serevent / Foradil / Inhalation / / Technology pharmacokinetics / / URL http /
SocialTag |
PULMONARY-ALLERGY DRUGS ADVISORY COMMITTEE MEETING January 29, 2013 NDA[removed]: olodaterol (proposed trade name Striverdi Respimat) for the proposed indication of long-term, once-daily maintenance bronchodilator treatmen